A B S T R A C TRenal pruritus (RP) is a condition or symptom that is often found in end-stagechronic kidney disease (CKD) undergoing hemodialysis (HD). The etiology of RP ismultifactorial, one of it due to inflammation mediated by interleukin 2 (IL-2). Studyon the correlation between serum level of IL-2 and the severity of RP is still limited.This study will analyze the correlation between serum level of IL-2 in patientsundergoing HD and the severity of RP. Our method is cross sectional design atHemodialysis Installation of Dr. Mohammad Hoesin Hospital. Serum level of IL-2examined by ELISA, the severity of RP assessed by a 5 dimensional pruritus scale.Inclusion criteria in this study included HD patients with RP ≥ 9, age ≥ 18 years andwilling to sign informed consent. The results from 28 male (59.6%) and 19 female(40.4%) are the mean serum level of IL-2 (pg/ml) is 0.424 ± 0.077. The mean RPseverity score is 18.98 ± 2.74. A strong positive correlation between serum level ofIL-2 and the severity of RP (r = 0.750, p = 0,000). Our conclusion is the increase ofserum level IL-2 in line with severity of RP.

Background: Seborrhoeic dermatitis (SD) is a chronic papulosquamous inflammatory disease which resistant to medical treatment. Various treatment such as topical corticosteroid, antifungal and calcineurin inhibitor has been widely practiced and gives varying results Objective: Our objective was to compare the efficacy of Sebclaira® and topical hydrocortisone 2,5% for management of moderate SD on the face Methods: A randomised clinical trial, controlled, double blind study was performed for four weeks. We assessed the efficacy and side effects of these topical treatment. The severity of SD was evaluated using Seborrhea Area Severity Index-Facial (SASI-F) score. The severity of pruritus was evaluated using Visual Analogue Scale. Demographic characteristics, baseline SASI-F and VAS were recorded in the medical record. Results: A 34 patients (14 males, 20 females) with moderate SD on the face completed the four weeks study. The mean of SASI T2 and VAS score of the Sebclaira® group was significantly lower than Hydrocortisone 2.5% group with p = 0.000 and p = 0.000 respectively. Tolerance between Sebclaira® and Hydrocortisone 2.5% showed insignificant results (p = 1.000) Conclusions: The longer application of Sebclaira® was significantly more effective to improve moderate SD

Renal pruritus (RP) is a condition or symptom that is often found in end-stage chronic kidney disease (CKD) undergoing hemodialysis (HD). The etiology of RP is multifactorial, one of it due to inflammation mediated by interleukin 2 (IL-2). Study on the correlation between serum level of IL-2 and the severity of RP is still limited. This study will analyze the correlation between serum level of IL-2 in patients undergoing HD and the severity of RP. Our method is cross sectional design at Hemodialysis Installation of Dr. Mohammad Hoesin Hospital. Serum level of IL-2 examined by ELISA, the severity of RP assessed by a 5 dimensional pruritus scale. Inclusion criteria in this study included HD patients with RP ≥ 9, age ≥ 18 years and willing to sign informed consent. The results from 28 male (59.6%) and 19 female (40.4%) are the mean serum level of IL-2 (pg/ml) is 0.424 ± 0.077. The mean RP severity score is 18.98 ± 2.74. A strong positive correlation between serum level of IL-2 and the severity of RP (r = 0.750, p = 0,000). Our conclusion is the increase of serum level IL-2 in line with severity of RP.